2021-11-02T07:44:36-05:00 2020-12-31 560747981 DIXON HUGHES GOODMAN LLP 901 EAST CARY STREET SUITE 1000 RICHMOND VA 23219 990 2020-01-01 521986675 FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH INC FOUN 3014025311 11400 ROCKVILLE PIKE NO 600 NORTH BETHESDA MD 20852 DONALD M HILL CHIEF FINANCIAL OFFICER 3014025311 2021-10-26 1 DONALD HILL 999009999 LAKRISHA J WATSON P01677333 8042827636 2021-10-06 2 AAL1 IAL1 2020 2022-09-23 18:48:47Z DONALD M HILL 11400 ROCKVILLE PIKE NO 600 NORTH BETHESDA MD 20852 215637725 0 X HTTP://WWW.FNIH.ORG X 1996 MD THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH CREATES AND MANAGES ALLIANCES WITH PUBLIC ANDPRIVATE INSTITUTIONS IN SUPPORT OF THE MISSION OF THE NIH, THE WORLD'S PREMIER MEDICAL RESEARCH AGENCY. THE FOUNDATION, ALSO KNOWN AS THE FNIH, WORKS WITH ITS PARTNERS TO ACCELERATE BIOMEDICAL RESEARCH AND STRATEGIES AGAINST DISEASES AND HEALTH CONCERNS IN THE UNITED STATES AND ACROSS THE GLOBE. THE FNIH ORGANIZES AND ADMINISTERS RESEARCH PROJECTS; SUPPORTS EDUCATION AND TRAINING OF NEW RESEARCHERS; ORGANIZES EDUCATIONAL EVENTS AND SYMPOSIA; AND ADMINISTERS A SERIES OF FUNDS SUPPORTING A WIDE RANGE OF HEALTH ISSUES. ESTABLISHED BY CONGRESS IN 1990, THE FNIH IS A NOT-FOR-PROFIT 501(C)(3) CHARITABLE ORGANIZATION. 26 25 75 25 0 0 50623645 98343956 -50000 0 3163912 1793315 81334 42551 53818891 100179822 34101314 23094805 0 0 9981336 11036676 24000 0 213544 23317958 24522875 67424608 58654356 -13605717 41525466 135541703 171939741 17031413 10735525 118510290 161204216 X SEE SCHEDULE O, STATEMENT OF ORGANIZATION'S PRIMARY EXEMPT PURPOSE STATEMENTTHE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH CREATES AND LEADS ALLIANCES AND PUBLIC-PRIVATE PARTNERSHIPS THAT ADVANCE BREAKTHROUGH BIOMEDICAL DISCOVERIES AND IMPROVE THE QUALITY OF PEOPLE'S LIVES. 0 0 51086040 22332809 0 SEE SCHEDULE O, PROGRAM ONE, RESEARCH PROGRAMSPROGRAM ONE - RESEARCH PROGRAMS -ACCELERATING COVID-19 THERAPEUTIC INTERVENTIONS AND VACCINES (ACTIV)IN A YEAR TURNED UPSIDE-DOWN BY THE COVID-19 PANDEMIC, THE WORLD LOOKED TO SCIENCE FOR ANSWERSAND THE FNIH WAS A LEADER IN ACCELERATING THE SEARCH FOR SOLUTIONS. CONVENING AND DIRECTING THE ACCELERATING COVID-19 THERAPEUTIC INTERVENTIONS AND VACCINES (ACTIV) PUBLIC-PRIVATE PARTNERSHIP IN APRIL 2020, THE FNIH HAS SUPPORTED AND GUIDED THE EFFORTS OF MULTIPLE U.S. GOVERNMENT AGENCIES, NONPROFIT ORGANIZATIONS AND INDUSTRY PARTNERS, ALL WORKING TOGETHER TO DEVELOP COVID-19 VACCINES AND TREATMENTS.WITH HUNDREDS OF POTENTIAL THERAPEUTIC INTERVENTIONS UNDER CONSIDERATION, MANY OF THEM INITIATED BY RESEARCH INSTITUTIONS IN SMALL, UNDERPOWERED, NON-RANDOMIZED TRIALS, A FIRST ORDER OF BUSINESS WAS TO IDENTIFY AND FOCUS CRITICAL RESOURCES ON THE MOST PROMISING CANDIDATES. ACTIV SIFTED THROUGH HUNDREDS OF POTENTIAL THERAPEUTIC CANDIDATES TO PRIORITIZE THOSE MOST SUITABLE FOR CLINICAL DEVELOPMENT AND THEN HELPED DEVELOP A ROBUST, CENTRALIZED SUITE OF "MASTER PROTOCOL" CLINICAL TRIALS SPONSORED BY NIH AND FUNDED BY OPERATION WARP SPEED, IN WHICH TO TEST THEM. MASTER PROTOCOLS ALLOW RESEARCHERS TO EVALUATE MULTIPLE TREATMENT OPTIONS AT ONCE AGAINST A SINGLE CONTROL ARM, MAKING TRIALS MUCH MORE EFFICIENT AND GETTING POTENTIALLY LIFESAVING TREATMENTS EVALUATED AT MULTIPLE HOSPITALS AND CLINICS MORE EFFECTIVELY. ACTIV WAS CRITICAL TO IDENTIFYING, PRIORITIZING AND STANDARDIZING THE RESOURCES NEEDED TO PERFORM PRECLINICAL TESTING ON PROMISING THERAPEUTIC AGENTS PRIOR TO TESTING IN HUMANS.ACTIV ALSO ENABLED VACCINE DEVELOPERS TO COLLABORATE IN THE DEVELOPMENT OF HARMONIZED PROTOCOLS FOR VACCINE EFFICACY TRIALS SO THAT FINDINGS COULD BE MORE EASILY COMPARED AND ASSISTED FDA IN UNDERSTANDING THE REQUIREMENTS FOR EARLY USE AUTHORIZATIONS FOR THESE VACCINES. IN CONCERT WITH GOVERNMENT AND COMPANY EFFORTS, ACTIV PLAYED AN IMPORTANT SUPPORTING ROLE IN THE DEVELOPMENT OF COVID-19 VACCINES IN A BREATHTAKING 11 MONTHS, COMPARED WITH THE TEN YEARS OR MORE OFTEN REQUIRED.THE SCALE AND SPEED OF THE ACTIV COLLABORATION IS UNPRECEDENTED, AND IN CONVENING IT THE FNIH HELPED ITS PARTNERS RISE TO MEET THE URGENT NEED TO ADDRESS THE GLOBAL PANDEMIC. USING ITS DEEP EXPERIENCE IN MANAGING PUBLIC-PRIVATE RESEARCH PARTNERSHIPS, THE FNIH QUICKLY BROUGHT TOGETHER THE PEOPLE AND ORGANIZATIONS WITH THE RIGHT KNOWLEDGE, ABILITIES AND VIEWPOINTS TO ADDRESS THIS GLOBAL PUBLIC HEALTH EMERGENCY AND PROVIDED AN ENVIRONMENT TO FACILITATE THEIR COMBINED KNOWLEDGE. ACTIV HAS DEMONSTRATED THAT WE CAN INDEED MAKE RAPID PROGRESS TO ADDRESS COVID-19AS WELL AS THE OTHER BIOMEDICAL CHALLENGES OF OUR ERABY WORKING TOGETHER IN THE RIGHT PARTNERSHIP FRAMEWORK.GENECONVENEMALARIA REMAINS ONE OF THE WORLD'S DEADLIEST DISEASES, KILLING SOME 400,000 PEOPLEPRIMARILY YOUNG CHILDRENEVERY YEAR. MALARIA IS BOTH PREVENTABLE AND TREATABLE, YET STUBBORNLY PERSISTENT, IN PART BECAUSE CONTROL EFFORTS SUCH AS INSECTICIDE-TREATED MOSQUITO NETS, INDOOR RESIDUAL SPRAYING AND SEASONAL CHEMOPREVENTION REQUIRE SUBSTANTIAL FINANCIAL COMMITMENT, POLITICAL SUPPORT AND DAY-TO-DAY BEHAVIOR CHANGE AMONG INDIVIDUALS AND HOUSEHOLDS.NEW GENETIC BIOCONTROL TECHNOLOGIES COULD MAKE IT POSSIBLE TO REDUCE THE TOLL OF MALARIA EITHER BY REDUCING THE REPRODUCTION OF MALARIA-CARRYING MOSQUITOES, SO FEWER WILL BE PRESENT TO SPREAD DISEASE, OR BY DECREASING THEIR ABILITY TO CARRY THE MALARIA PARASITE. WITH MOSQUITOES NO LONGER TRANSMITTING MALARIA, INDIVIDUALS WOULD BE FREE OF SPECIAL PROTECTION MEASURES AND COMMUNITIES WOULD ENJOY EXTRAORDINARY SOCIAL, ECONOMIC AND HEALTH BENEFITS.IT'S AN INSPIRING YET CHALLENGING VISION, RAISING IMPORTANT TECHNICAL, REGULATORY AND ETHICAL QUESTIONS. AND WHILE THE SCIENTIFIC COMMUNITY HAS ESTABLISHED PROCEDURES FOR EVALUATING TOOLS LIKE VACCINES, MEDICINES AND INSECTICIDES, SUCH PROCEDURES HAVE NOT YET BEEN DEVELOPED FOR GENETIC BIOCONTROL. THAT'S WHY IN 2020 THE FNIH LAUNCHED THE GENECONVENE GLOBAL COLLABORATIVE, AN INITIATIVE TO ADVANCE THE SAFE AND RESPONSIBLE EXPLORATION OF GENETIC BIOCONTROL TECHNOLOGIES. BUILDING ON MORE THAN A DECADE OF FNIH WORK, GENECONVENE BRINGS TOGETHER SCIENTISTS, REGULATORS, POLICYMAKERS AND OTHER STAKEHOLDERS TO DEVELOP BEST PRACTICES AND ENSURE THAT GENETIC BIOCONTROL RESEARCH ADDRESSES IMPORTANT PUBLIC HEALTH PRIORITIES ETHICALLY, SAFELY AND EFFECTIVELY.GENECONVENE ALSO SERVES AS A GLOBAL HUB FOR RELEVANT, TIMELY AND ACCURATE KNOWLEDGE. A KEY RESOURCE FOR THIS WORK IS THE GENECONVENE VIRTUAL INSTITUTE, ALSO LAUNCHED IN 2020. THE VIRTUAL INSTITUTE IS AN ONLINE LIBRARY HOUSING SCHOLARLY LITERATURE, POLICY PAPERS, OPINION PIECES, EDUCATIONAL VIDEOS AND MEDIA COVERAGE. GENECONVENE ALSO HOSTS REGULAR WEBINARS THAT PROVIDE DIVERSE, MULTIDISCIPLINARY PERSPECTIVES ON THE SCIENTIFIC, SOCIAL AND ETHICAL DIMENSIONS OF GENETIC BIOCONTROL TECHNOLOGIES.REALIZING THE IMMENSE PROMISE OF GENETIC BIOCONTROL RESEARCH TO END MALARIA AND OTHER MOSQUITO-BORNE DISEASES OVER THE LONG TERM WILL REQUIRE A RIGOROUS EVALUATION OF THE RISKS AND BENEFITS OF EACH STEP ALONG THE WAY, FROM THE LABORATORY TO FIELD TESTING TO POTENTIAL IMPLEMENTATION. THROUGH THE GENECONVENE GLOBAL COLLABORATIVE, FNIH IS COMMITTED TO ENSURING THAT EVERYONE CHARGED WITH MAKING DECISIONS ABOUT GENETIC BIOCONTROLFROM SCIENTISTS TO POLICYMAKERS TO COMMUNITIESHAS THE KNOWLEDGE THEY NEED TO MOVE FORWARD SAFELY AND ETHICALLY.A-PLUS TRIALEVERY YEAR GLOBALLY, MORE THAN TWO MILLION BABIES DIE SHORTLY AFTER BIRTH, WHILE NEARLY 300,000 WOMEN DIE FROM PREVENTABLE CAUSES RELATED TO PREGNANCY AND CHILDBIRTH. MANY OF THESE DEATHSABOUT 10 PERCENT OF MATERNAL MORTALITY AND ABOUT 16 PERCENT OF NEONATAL MORTALITYARE CAUSED BY INFECTION, AND MANY OCCUR IN LOW- AND MIDDLE-INCOME COUNTRIES. DESPITE THE WIDESPREAD AVAILABILITY OF ANTIBIOTICS, THERE HAS BEEN LITTLE RECENT PROGRESS IN REDUCING THIS TOLL.IN 2020, THE FNIH ANNOUNCED THE LAUNCH OF A NEW INITIATIVE TO ADVANCE RESEARCH ON A SIMPLE BUT INNOVATIVE INTERVENTION THAT COULD BE A GAME-CHANGER FOR PREVENTING MATERNAL AND NEWBORN DEATH. LAUNCHED IN PARTNERSHIP WITH THEEUNICE KENNEDY SHRIVERNATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT WITH FUNDING FROM THE BILL & MELINDA GATES FOUNDATION, THE MULTI-SITE EFFICACY AND SAFETY TRIAL OF INTRAPARTUM AZITHROMYCIN IN LOW- AND MIDDLE-INCOME COUNTRIES, ALSO CALLED THE A-PLUS STUDY, WILL ASSESS HOW WELL A SINGLE ORAL DOSE OF AZITHROMYCIN DURING LABOR CAN PROTECT THE HEALTH OF BOTH MOTHERS AND NEWBORNS.RECENT PRELIMINARY TRIALS OF PROVIDING AZITHROMYCIN DURING LABOR IN THE U.S. AND THE GAMBIA HAVE SHOWN PROMISING RESULTS, BUT A MUCH LARGER STUDY IS NEEDED TO CONFIRM THESE FINDINGS. THE A-PLUS TRIAL WILL ENROLL 34,000 WOMEN ACROSS SOUTH ASIA, SUB-SAHARAN AFRICA AND CENTRAL AMERICA. IF THE RESULTS OF THIS LARGE, THREE-YEAR TRIAL SHOW THAT PROPHYLACTIC TREATMENT LEADS TO FEWER INFECTIONS AND DEATHS, IT COULD INITIATE A TRANSFORMATION IN PRACTICE AT PARTICIPATING SITES AND NEW GUIDELINES FROM THE WORLD HEALTH ORGANIZATION AND OTHER PROFESSIONAL ORGANIZATIONS, POTENTIALLY SAVING THE LIVES OF MOTHERS AND BABIES AROUND THE WORLD.ACCELERATING MEDICINES PARTNERSHIP IN SCHIZOPHRENIA (AMP SCZ)SCHIZOPHRENIA, WHICH AFFECTS APPROXIMATELY 20 MILLION PEOPLE WORLDWIDE, IS ONE OF THE BEST-0KNOWN YET LEAST-UNDERSTOOD BRAIN DISORDERS. SYMPTOMS OFTEN EMERGE DURING THE TEENAGE YEARS OR EARLY ADULTHOOD, BUT THIS SERIOUS MENTAL DISORDER IS USUALLY NOT DIAGNOSED UNTIL PSYCHOSIS OCCURS, WHICH MAY BE SEVERAL YEARS LATER. DIAGNOSING AND TREATING SCHIZOPHRENIA SOONER COULD HELP YOUNG PEOPLE STRUGGLING WITH ITS EARLY SYMPTOMS AND POTENTIALLY DELAY OR STOP DISEASE PROGRESSION.THE FNIH'S ACCELERATING MEDICINES PARTNERSHIP IN SCHIZOPHRENIA (AMP SCZ), LAUNCHED IN SEPTEMBER 2020, AIMS TO IDENTIFY EARLY INDICATORS OF THE DISEASE, WHICH WILL ALLOW RESEARCHERS TO TEST NEW TREATMENTS THAT COULD DIAGNOSE AND HELP PATIENTS IN ITS INITIAL STAGES. THIS FIVE-YEAR, $99 MILLION PROJECT BRINGS TOGETHER NINE PARTNERS, INCLUDING GOVERNMENT AGENCIES, INDUSTRY, PRIVATE FOUNDATIONS AND PATIENT-CENTERED NOT-FOR-PROFIT ORGANIZATIONS, TO COLLABORATE IN THIS CRITICAL WORK. TOGETHER, THE PARTNERS ARE:- ESTABLISHING TWO RESEARCH NETWORKS CONNECTING OVER 40 U.S. AND INTERNATIONAL SITES WORKING WITH INDIVIDUALS AT HIGH RISK, ALLOWING IMPROVED COORDINATION AND ENHANCING APPLICABILITY OF RESULTS TO GLOBAL POPULATIONS- SUPPORTING RAPID ANALYSIS AND DISSEMINATION OF DATA THROUGH A STATE-OF-THE-SCIENCE DATA PROCESSING CENTER AND THE NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH) DATA ARCHIVE, ALLOWING THE BROADER BIOMEDICAL RESEARCH COMMUNITY OPEN ACCESS AND EXTENDING THE REACH AND IMPACT OF THE WORK 1062478 761996 0 SEE SCHEDULE O, PROGRAM TWO, AWARDS, EVENTS, EDUCATION/TRAINING PROGRAMSPROGRAM TWO - AWARDS, EVENTS, EDUCATION/TRAINING PROGRAMS - INVESTING IN THE FUTURE OF SCIENTIFIC LEADERSHIP ONE OF THE MANY WAYS THE FNIH ACCELERATES PROGRESS IS THROUGH INVESTMENT IN THE CREATIVITY OF EXCEPTIONAL SCIENTISTS. THE ORGANIZATION BESTOWS THREE PRIZES EACH YEAR TO RECOGNIZE OUTSTANDING PARTNERS AND CONTRIBUTORS TO ADVANCING BIOMEDICAL RESEARCH. LURIE PRIZE IN BIOMEDICAL SCIENCELURIE PRIZE IN BIOMEDICAL SCIENCES IS AN ANNUAL PRIZE MADE POSSIBLE BY A GENEROUS GIFT FROM PHILANTHROPIST ANN LURIE, RECOGNIZING OUTSTANDING ACHIEVEMENTS MADE BY A PROMISING YOUNG SCIENTIST. IN 2020, THE FNIH HONORED AVIV REGEV, PH.D., FOR HER GROUNDBREAKING WORK DEVELOPING THE FIELD OF SINGLE-CELL GENOMICS. AT THAT TIME, DR. REGEV WAS CORE MEMBER, CHAIR OF THE FACULTY AND DIRECTOR OF THE KLARMAN CELL OBSERVATORY AT THE BROAD INSTITUTE OF MIT AND HARVARD.DR. REGEV'S WORK SPEARHEADING NEW TECHNOLOGIES THAT ENABLE A SHARPER PERSPECTIVE ON HUMAN CELLS HAS LED TO KEY INSIGHTS ABOUT HOW CELLS FUNCTION AND HAS REVOLUTIONIZED OUR UNDERSTANDING OF BIOLOGY AND DISEASES, INCLUDING CANCER AND AUTOIMMUNE DISORDERS.DR. REGEV IS A CO-FOUNDER AND CO-LEADER OF THE HUMAN CELL ATLAS, AN INTERNATIONAL COMMUNITY OF MORE THAN 1,800 SCIENTISTS WORKING TO CREATE COMPREHENSIVE REFERENCE MAPS OF ALL HUMAN CELLS. SHE IS CURRENTLY EXECUTIVE VICE PRESIDENT OF GENENTECH RESEARCH AND EARLY DEVELOPMENT.TRAILBLAZER PRIZE FOR CLINICIAN-SCIENTISTSTHE TRAILBLAZER PRIZE WAS ESTABLISHED IN 2018 TO HIGHLIGHT THE ESSENTIAL ROLE OF EARLY CAREER CLINICIAN-SCIENTISTS IN SPURRING INNOVATION IN PATIENT CARE.IN 2020, MICHAEL WILSON, M.D., ASSOCIATE PROFESSOR OF NEUROLOGY IN THE DIVISION OF NEUROIMMUNOLOGY AND GLIAL BIOLOGY AT THE UCSF WEILL INSTITUTE FOR NEUROSCIENCES, WAS AWARDED THE PRIZE FOR PIONEERING A NEXT-GENERATION DIAGNOSTIC APPROACH TO PINPOINT INFECTIOUS CAUSES OF INFLAMMATORY CONDITIONS OF THE CENTRAL NERVOUS SYSTEM.DR. WILSON'S INNOVATIVE TECHNIQUE OF METAGENOMIC NEXT-GENERATION SEQUENCING ALLOWS PRECISE IDENTIFICATION OF THE SPECIFIC INFECTIOUS AGENTS CAUSING INFLAMMATION IN A PATIENT, WHILE RULING OUT IRRELEVANT PATHOGENS THAT MIGHT OTHERWISE HAVE BEEN SUSPECTED. USING THIS APPROACH, DR. WILSON HAS UNEARTHED KEY KNOWLEDGE ABOUT THE INFECTIOUS AND AUTOIMMUNE CAUSES OF INFLAMMATORY CONDITIONS IN THE BRAIN, SPINAL CORD AND MENINGES, INCLUDING MAJOR DISCOVERIES SUCH AS CO-IDENTIFYING THE FAMILY OF VIRUSES BEHIND ACUTE FLACCID MYELITIS, A PARALYZING, POLIO-LIKE CONDITION AFFECTING CHILDREN. FUNDING FOR THE TRAILBLAZER PRIZE IS PROVIDED BY THE GALLIN FUND AT THE FNIH.CHARLES A. SANDERS, M.D., PARTNERSHIP AWARDEACH YEAR, THE FNIH BESTOWS THE CHARLES A. SANDERS, M.D., PARTNERSHIP AWARD TO RECOGNIZE PEOPLE AND/OR ORGANIZATIONS THAT HAVE MADE SIGNIFICANT CONTRIBUTIONS TO THE ORGANIZATION'S EFFORTS TO BUILD, IMPLEMENT AND NURTURE PUBLIC-PRIVATE PARTNERSHIPS IN SUPPORT OF THE MISSION OF THE NIH.IN 2020, THE FNIH HONORED ANTHONY S. FAUCI, M.D., LONG-TIME DIRECTOR OF THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID), FOR HIS LEGACY OF LEADERSHIP AND ONGOING SUPPORT OF FNIH PROGRAMS PROPELLING RESEARCH IN LETHAL INFECTIOUS DISEASES, MOST RECENTLY FOR COVID-19.AS NIAID DIRECTOR SINCE 1984, DR. FAUCI HAS BEEN AT THE FOREFRONT OF THE SCIENTIFIC RESPONSE TO PREVENT, DIAGNOSE AND TREAT THE WORLD'S MOST VEXING INFECTIOUS DISEASES, INCLUDING HIV/AIDS, ZIKA, EBOLA AND MANY OTHERS. OVER THE COURSE OF HIS EXTENSIVE CAREER, DR. FAUCI HAS OVERSEEN A WIDE VARIETY OF RESEARCH COLLABORATIONS BETWEEN NIAID AND THE FNIH, INCLUDING WORK IN AFRICA ON HIV/AIDS, AS WELL AS TUBERCULOSIS VACCINES, TREATMENTS AND BIOINFORMATICS. HE CURRENTLY SERVES ON THE EXECUTIVE COMMITTEE OF THE FNIH-COORDINATED ACCELERATING COVID-19 THERAPEUTIC INTERVENTIONS AND VACCINES (ACTIV) INITIATIVE, A PUBLIC-PRIVATE PARTNERSHIP TO EXPEDITE DEVELOPMENT OF VACCINES AND TREATMENTS FOR COVID-19.FUNDING FOR THE CHARLES A. SANDERS, M.D., PARTNERSHIP AWARD IS PROVIDED BY THE CHARLES A. SANDERS LEGACY FUND AT THE FNIH. 54582 0 0 SEE SCHEDULE O, PROGRAM THREE, PATIENT SUPPORT PROGRAM/CAPITAL PROJECTPROGRAM THREE - PATIENT SUPPORT PROGRAM/CAPITAL PROJECT -FILLING A NEED OF THE NATION'S LEADING RESEARCH CENTERAT THE NIH CLINICAL CENTER THE NATION'S PREMIER HOSPITAL SOLELY DEVOTED TO CLINICAL INVESTIGATION PATIENTS ARE CONSIDERED "ACTIVE PARTNERS IN MEDICAL DISCOVERY," PARTICIPATING IN EXPERIMENTAL TRIALS CARRIED OUT BY NIH INSTITUTES TO RECEIVE TREATMENT FOR THEIR CONDITIONS AND ULTIMATELY BENEFIT SCIENTIFIC PROGRESS. THE EXTENSIVE LIST OF RESEARCH BREAKTHROUGHS COMING OUT OF THE NIH CLINICAL CENTER INCLUDES THE FIRST CURES FOR CHILDHOOD LEUKEMIA AND HODGKIN'S DISEASE USING CHEMOTHERAPY, THE FIRST BLOOD TESTS FOR AIDS AND HEPATITIS, AND THE FIRST GENE THERAPY, TO NAME JUST A FEW. TO SUPPORT SUCH RESOURCE-INTENSIVE ENDEAVORS, THE FNIH ESTABLISHED THE CLINICAL CENTER IN-KIND DRUG DONATION PROGRAM TO DONATE PHARMACEUTICALS TO THE NIH CLINICAL CENTER. THE PROGRAM, WHICH HAS PROVIDED NEARLY $16 MILLION IN DRUGS AND THERAPEUTICS TO THE NIH SINCE 2008, WAS SUPPORTED IN 2019 BY A MAJOR GIFT FROM HORIZON THERAPEUTICS PLC. "THE GENEROSITY OF THE PROGRAM HAS BEEN A MAJOR BOON TO OUR PATIENTS AND OUR PROGRAM," SAYS DR. STEVEN HOLLAND, DIRECTOR, DIVISION OF INTRAMURAL RESEARCH AT NIAID. 52203100 1 1 0 1 0 1 0 0 0 1 1 0 0 0 1 1 1 0 0 0 1 1 0 0 1 0 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 35 0 1 75 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 26 25 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MD VA NY AL AR CA FL GA HI IL KS KY MA MI MS MN NH NJ NM OR PA RI SC TN UT WV WI X X DONALD M HILL 3014356246 11400 ROCKVILLE PIKE SUITE 600 NORTH BETHESDA MD 20852 X DR STEVEN M PAUL CHAIRMAN 1.50 X X 0 0 0 DR SOLOMON H SNYDER VICE-CHAIRMAN 0.50 X X 0 0 0 MR STEVEN C MAYER TREASURER 2.00 X X 0 0 0 MRS WILLIAM MCCORMICK BLAIR JR SECRETARY 1.00 X X 0 0 0 DR MARIA C FREIRE PRESIDENT AND EXECUTIVE DIRECTOR 40.00 X X 516856 0 31250 DR KATHY BLOOMGARDEN BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MRS WILLIAM N CAFRITZ BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR MARIJN DEKKERS BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MR JAMES H DONOVAN BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR PAUL L HERRLING BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR THOMAS R INSEL BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR JUDY LANSING KOVLER BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR RONALD L KRALL BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR FREDA C LEWIS-HALL BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 JULIE BELL LINDSAY BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR EDISON T LIU BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MR JOEL S MARCUS BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR PAUL M MONTRONE BOARD OF DIRECTORS MEMBER UNTIL 5/20 0.50 X 0 0 0 DAME JILLIAN SACKLER BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MRS LILY SAFRA BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR CHARLES A SANDERS BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MR FRED SEIGEL BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR ELLEN V SIGAL BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MR RUSSELL W STEENBERG BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR PAUL STOFFELS BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR ELIAS ZERHOUNI BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 GILBERT S OMENN BOARD OF DIRECTORS MEMBER FROM 5/20 0.50 X 0 0 0 MR DONALD HILL CHIEF FINANCIAL OFFICER 40.00 X 254979 0 42966 MR KEVIN A KLOCK VP OF OPERATIONS & GENERAL COUNSEL 40.00 X 227164 0 40816 MR DAVID WHOLLEY SENIOR VP OF RESEARCH PARTNERSHIPS 40.00 X 373754 0 45750 DR STEPHANIE JAMES SENIOR VP OF SCIENCE 40.00 X 351650 0 28500 MICHAEL SANTOS ASSOCIATE VICE PRESIDENT OF SCIENCE 40.00 X 289646 0 35540 MS JULIE WOLF-RODDA SENIOR VP OF DEVELOPMENT 40.00 X 235610 0 39835 DR JOSEPH MENETSKI ASSOCIATE VP OF RESEARCH PARTNERSHIPS 40.00 X 235372 0 39381 MR ROBERT BALTHASER VICE PRESIDENT OF ADVANCEMENT 40.00 X 166026 0 23484 ABBEY MELTZER VP OF COMMUNICATIONS AND EVENTS 40.00 X 153421 0 29931 DR STACEY ADAM DIRECTOR OF CANCER RESEARCH PARTNERSHIPS 40.00 X 191762 0 26100 DR DAVID O'BROCHTA SCIENTIFIC PROGRAM MANAGER 40.00 X 188311 0 34874 DR KAREN TOUNTAS SCIENTIFIC PROGRAM MANAGER 40.00 X 186176 0 32182 BRINDA DASS SCIENTIFIC PROGRAM MANAGER 40.00 X 179292 0 27871 STEVEN HOFFMANN DIRECTOR OF INFLAMMATION & IMMNUNITY 40.00 X 171317 0 31699 3721336 0 510179 32 0 1 0 SWOG CTI 24 FRANK LLOYD WRIGHT DRIVE PO BOX ANN ARBOR MI 48105 CONDUCTS CLINICAL TRIAL FOR LUNGMAP 9208799 THE BROAD INSTITUTE INC 415 MAIN STREET CAMBRIDGE MA 02142 PROFESSIONAL SERVICES FOR THE AMP T2DIAB 2360378 DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON MA 02215 RESEARCH COLLABORATION AGREEMENT FOR THE 2253477 DELOITTE CONSULTING LLP 4022 SELLS DRIVE HERMITAGE TN 37076 PROFESSIONAL SERVICES FOR THE ACCELARATI 1758012 THE UNIVERSITY OF TEXASMD ANDERSON PO BOX 4266 HOUSTON TX 77210 RESEARCH COLLABORATION AGREEMENT FOR THE 1298453 28 72000 1250000 97021956 845251 98343956 1722957 1722957 115312812 115242454 70358 70358 70358 258000 72000 215449 42551 42551 100179822 0 0 1835866 20919453 20919453 358500 358500 1816852 1816852 2887178 1208525 1606141 72512 6264915 4192753 2009872 62290 626744 379706 229573 17465 1053496 709034 315615 28847 204343 278153 -73810 251071 135891 115180 172078 172078 24028 13944 10084 17849 9644 8175 30 121689 35000 66192 20497 738820 180012 558808 232941 218432 12140 2369 250896 250896 192613 120114 72499 PROGRAM CONTRACTS 19323011 19323011 CONSULTANTS 3863288 3441965 421323 RELOCATION 339228 339228 HONORARIA 119534 110000 9534 -1124171 -1247889 123718 58654356 52203100 6237712 213544 33010960 66486739 11954468 41358911 248256 235751 2948307 999474 1574395 1948833 88147149 59636280 606475 2273227 135541703 171939741 10145693 7166950 5147362 1331478 1738358 2237097 17031413 10735525 X 21577974 25368465 96932316 135835751 118510290 161204216 135541703 171939741 41525466 1168460 0 X X 0 1 X 1 1 1 X 82860385 61322159 60444618 50623645 98343956 353594763 82860385 61322159 60444618 50623645 98343956 353594763 146344040 207250723 574125 1066052 2057158 2818334 1722957 8238626 361833389 248775 0.57280 0.56230 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1 0 0 0 0 1 0 0 0 0 PART II-B, LINE 1: FNIH CONSULTED ITS CONGRESSIONAL COMMITTEES OF JURISDICTION ON PUBLIC HEALTH LEGISLATION. 1 3700 22444 234886 1 1 0 0 14897505 5648998 419982 88450 20878035 12514811 1788682 705900 111888 14897505 11920726 1032217 -267231 103397 67504 12514811 9704030 1721204 552828 57336 11920726 9501571 11412 243278 52231 9704030 0.74475 0.25525 0 0 1869159 330439 1538720 1079148 669035 410113 1948833 CHARITABLE GIFT ANNUITY 125764 DEFERRED LEASE INCENTIVE 1538721 DEFERRED RENT LIABILITY 572612 2237097 X 102041639 1168460 649986 1818446 100223193 172078 -215449 -43371 100179822 59347713 649986 215449 865435 58482278 172078 172078 58654356 PART V, LINE 4: THE FOUNDATION HAS ONE ENDOWMENT THAT IS FUNDED BY MULTIPLE DONORS TO SEED NEW DISCOVERIES AND/OR BE AVAILABLE TO RESPOND TO EPIDEMICS AND FOUNDATION'S UNANTICIPATED NEEDS. THE FOUNDATION'S OTHER ENDOWMENTS CONSIST OF INDIVIDUAL DONOR-RESTRICTED ENDOWMENT FUNDS ESTABLISHED FOR A VARIETY OF PURPOSE. (E.G. VARIETY OF RESEARCH AND EDUCATIONAL INITIATIVES AT THE FOUNDATION FOR THE NIH, INC). NET ASSETS ASSOCIATED WITH ENDOWMENT FUNDS ARE CLASSIFIED AND REPORTED BASED ON THE EXISTENCE OR ABSENCE OR DONOR-IMPOSED RESTRICTIONS. PART X, LINE 2: THE FOUNDATION IS EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE; ACCORDINGLY, THE ACCOMPANYING FINANCIAL STATEMENTS DO NOT REFLECT A PROVISION OR LIABILITY FOR FEDERAL AND STATE INCOME TAXES. THE FOUNDATION HAS DETERMINED THAT IT DOES NOT HAVE ANY MATERIAL UNRECOGNIZED TAX BENEFITS OR OBLIGATIONS AS OF DECEMBER 31, 2020 AND 2019. PART XI, LINE 4B - OTHER ADJUSTMENTS: FUNDRAISING DIRECT EXPENSE -215,449. PART XII, LINE 2D - OTHER ADJUSTMENTS: FUNDRAISING DIRECT EXPENSE 215,449. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTMAKING 878719 EAST ASIA AND THE PACIFIC 0 0 GRANTMAKING 39477 SUB-SAHARAN AFRICA 0 0 GRANTMAKING 898656 0 0 0 0 0 0 1816852 0 1816852 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM RESEARCH 229325 WIRE TRANSFER SUB-SAHARAN AFRICA - ANGOLA, BENIN, BOTSWANA, BURKINA FASO, RESEARCH 227449 WIRE TRANSFER SUB-SAHARAN AFRICA - ANGOLA, BENIN, BOTSWANA, BURKINA FASO, RESEARCH 671207 WIRE TRANSFER EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, RESEARCH 39477 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM RESEARCH 71323 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM RESEARCH 285414 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM RESEARCH 292657 WIRE TRANSFER 1 6 0 0 0 0 0 0 PART I, LINE 2: PROGRAM AND GRANTS MANAGEMENT STAFF INVEST CONSIDERABLE EFFORT IN PROVIDING SCIENTIFIC, ADMINISTRATIVE, AND FISCAL OVERSIGHT FOR FNIH GRANTS. SCIENTIFIC AND TECHNICAL PROGRESS IS MONITORED THROUGH SEMI-ANNUAL AND ANNUAL REPORTS FROM THE GRANTEES AS WELL AS THROUGH DIRECT CONTACT WITH INVESTIGATORS BOTH BY TELECONFERENCE AND SITE VISITS, AND FOLLOW UP TO PROGRESS REPORTS AND SITE VISITS WHERE SCIENTIFIC QUESTIONS OR ADMINISTRATIVE ISSUES ARE IDENTIFIED. SCIENTIFIC REPORT SUBMISSIONS COVER A WIDE RANGE OF ITEMS INCLUDING INDIVIDUAL OBJECTIVES AND OVERALL PROGRESS REVIEW, MILESTONE ACHIEVEMENT, PROJECT PLAN UPDATE, AND ANY OTHER SIGNIFICANT CHANGES. FINANCIAL REPORTING IS REQUIRED ANNUALLY FOR ALL OF THE GRANTEES, AND SEMI-ANNUALLY FOR INSTITUTIONS THAT REQUIRE ADDITIONAL OVERSIGHT, SUCH AS SOME DEVELOPING COUNTRY INSTITUTIONS. DUE DILIGENCE PROCEDURES, SUCH AS FNIH COMPLIANCE WITH THE USA PATRIOT ACT AND IRS REQUIREMENTS ON EXPENDITURE RESPONSIBILITIES, HAVE BEEN INCORPORATED INTO THE REPORTING PROCESS TO ENSURE THAT THE GRANTEES ARE COMPLYING WITH GRANT, LEGAL, FINANCIAL, AND REGULATORY REQUIREMENTS. PART III ACCOUNTING METHOD: 2020 FNIH AWARD CEREMONY 330000 72000 258000 303 189780 2021 FNIH AWARD CEREMONY 25366 330000 72000 258000 303 215146 215449 42551 1 NIHCC - CLINICAL CENTER 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 409444 RESEARCH NIHNATIONAL INSTITUTE ON AGING 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 2774181 RESEARCH NIHNCI 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 2860444 RESEARCH NIHNIAID 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 3216529 RESEARCH NIHNIAMS 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 3533808 RESEARCH NIHNINDS 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 542086 RESEARCH THE TRUSTEES OF COLUMBIA UNIVERSITY PO BOX 29789 GENERAL POST OFFICE NEW YORK NY 100879789 135598093 501(C)(3) 767983 RESEARCH TRUSTEES OF INDIANA UNIVERSITY THE POPLARS BUILDING400 E SEVENTH ST BLOOMINGTON IN 474053085 356001673 501(C)(3) 226585 RESEARCH UNIVERSITY OF VIRGINIA PO BOX 400195 CHARLOTTESVILLE VA 22904 546001796 501(C)(3) 240083 RESEARCH UNIVERSITY OF COLORADO DENVER PO BOX 910238 DENVER CO 80291 846000555 501(C)(3) 215016 RESEARCH CASE WESTERN RESERVE UNIVERSITY NORD HALL SUITE 615 10900 EUCLID AVENUE CLEVELAND OH 44106 341018992 501(C)(3) 539772 RESEARCH UNIVERSITY OF LOUISIANA AT LAFAYETTE 4401 W ADMIRAL DOYLE DRIVE NEW IBERIA LA 70560 726023836 501(C)(3) 544987 RESEARCH DUKE UNIVHUMAN VACCINE INSTITUTE 2200 WEST MAIN STREET SUITE 820 ERWIN SQUARE PLAZA DURHAM NC 27705 560532129 501(C)(3) 196891 RESEARCH FRED HUTCHINSON CANCER RESEARCH CTR 1100 FAIRVIEW AVE N SEATTLE WA 98109 237156071 501(C)(3) 444646 RESEARCH CATALYSIS FOUNDATION FOR HEALTH INC 1900 POWELL STREET SUITE 600 EMERYVILLE CA 94608 208602047 501(C)(3) 238789 RESEARCH UNIVERSITY OF PITTSBURGH 200 LOTHROP ST BIOMEDICAL SCIENCE TOWER W 950 PITTSBURGH PA 15213 250965591 501(C)(3) 343422 RESEARCH REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET 1040 WOLVERINE TOWER ANN ARBOR MI 48109 386006309 501(C)(3) 1000000 RESEARCH TRUSTEE OF BOSTON UNIVERSITY FOR THE BOSTON UNIVERSITY MEDICAL SCHOOL PO BOX 28763 GRANT RECEIVABLE NEW YORK NY 100878763 042103547 501(C)(3) 150000 RESEARCH JOHNS HOPKINS UNIVERSITY 615 N WOLFE ST W1100 BALTIMORE MD 21205 150595110 501(C)(3) 30000 RESEARCH REGENTS OF THE UOF CALIFORNIASAN FRANCISCO MISSION HALL 550 16TH STREET 2ND FLOOR SAN FRANCISCO CA 94143 946036493 501(C)(3) 27576 RESEARCH BRIGHAM & WOMEN'S HOSPITAL 1620 TREMONT STREET 3RD FLOOR RM BC 3002 BOSTON MA 02120 042312909 501(C)(3) 232921 RESEARCH FRIENDS OF CANCER RESEARCH 1800 M STREET NW SUITE 1050 SOUTH WASHINGTON DC 20036 521983273 501(C)(3) 216611 RESEARCH UNIVERSITY OF SOUTHERN CALIFORNIA SOTO STREET BUILDING 2001 SOTO STREET LOS ANGELES CA 900899235 911642394 501(C)(3) 1150000 RESEARCH WESTERN MICHIGAN UNIVERSITY 1903 W MICHIGAN AVENUE KALAMAZOO MI 49008 386007327 501(C)(3) 534892 RESEARCH TRANSLATIONAL GENOMICS RESEARCH INSTITUTE 446 N FIFTH STREET SUITE 600 PHOENIX AZ 85005 331092191 501(C)(3) 86764 RESEARCH LEIDOS BIOMEDICAL RESEARCH INC 1050 BOYLES STREET FREDERICK MD 21702 330653185 396023 RESEARCH AND DEVELOPMENT 25 1 AWARDS 11 358500 FMV PART I, LINE 2: PROGRAM AND GRANTS MANAGEMENT STAFF INVEST CONSIDERABLE EFFORT IN PROVIDING SCIENTIFIC, ADMINISTRATIVE, AND FISCAL OVERSIGHT FOR FNIH GRANTS. SCIENTIFIC AND TECHNICAL PROGRESS IS MONITORED THROUGH SEMI-ANNUAL AND ANNUAL REPORTS FROM THE GRANTEES AS WELL AS THROUGH DIRECT CONTACT WITH INVESTIGATORS BOTH BY TELECONFERENCE AND SITE VISITS, AND FOLLOW UP TO PROGRESS REPORTS AND SITE VISITS WHERE SCIENTIFIC QUESTIONS OR ADMINISTRATIVE ISSUES ARE IDENTIFIED. SCIENTIFIC REPORT SUBMISSIONS COVER A WIDE RANGE OF ITEMS INCLUDING INDIVIDUAL OBJECTIVES AND OVERALL PROGRESS REVIEW, MILESTONE ACHIEVEMENT, PROJECT PLAN UPDATE, AND ANY OTHER SIGNIFICANT CHANGES. FINANCIAL REPORTING IS REQUIRED ANNUALLY FOR ALL OF THE GRANTEES, AND SEMI-ANNUALLY FOR INSTITUTIONS THAT REQUIRE ADDITIONAL OVERSIGHT, SUCH AS FOR-PROFIT INSTITUTIONS. DUE DILIGENCE PROCEDURES, SUCH AS FNIH COMPLIANCE WITH THE USA PATRIOT ACT AND IRS REQUIREMENTS ON EXPENDITURE RESPONSIBILITIES, HAVE BEEN INCORPORATED INTO THE REPORTING PROCESS TO ENSURE THAT THE GRANTEES ARE COMPLYING WITH GRANT, LEGAL, FINANCIAL, AND REGULATORY REQUIREMENTS. FELLOWS SELECTED FOR FOUNDATION FELLOWSHIPS ARE SELECTED THROUGH NATIONWIDE AND INTERNATIONAL COMPETITIONS. THE CLINICAL RESEARCH TRAINING PROGRAM (CRTP) IS OPEN TO ALL THIRD YEAR STUDENTS ENROLLED IN MEDICAL OR DENTAL SCHOOLS. THE WOMEN'S HEALTH FELLOWSHIP PROGRAMS ARE OPEN TO DOCTORAL-LEVEL CANDIDATES WITHIN FIVE YEARS OF RECEIPT OF THE DOCTORAL DEGREE. APPLICATIONS, CONTAINING TRANSCRIPTS AND ESSAYS ON THEIR RESEARCH GOALS ARE SUBMITTED AND REVIEWED BY PANELS OF NIH SCIENTISTS WHO MAKE RECOMMENDATIONS FOR SELECTION. POTENTIAL FELLOWS ARE OFTEN BROUGHT TO THE CAMPUS FOR INTERVIEWS AND FINAL SELECTION. THE FOUNDATION'S FELLOWSHIPS ARE OPEN TO PROFESSIONALS WORKING AT VARIOUS STAGES OF THEIR RESEARCH CAREERS. APPLICANTS TO THE NEUROSCIENCE FELLOWSHIP, FOR EXAMPLE, ARE YOUNG SCIENTISTS WHO WILL BENEFIT FROM EXPERIENCE OF CLINICAL AND BASIC SCIENCE RESEARCH. THE DIRECTOR'S FELLOWSHIP IN COMPLEMENTARY AND ALTERNATIVE MEDICINE RESEARCH SEEKS A MORE EXPERIENCED SCIENTIST WHO IS WELL-POSITIONED TO BECOME A LEADER IN THE FIELD OF COMPLEMENTARY ALTERNATIVE MEDICINE. X X X X X 0 0 0 0 0 0 0 0 0 DR MARIA C FREIRE PRESIDENT AND EXECUTIVE DIRECTOR 491856 0 25000 0 0 0 28500 0 2750 0 548106 0 0 0 MR DAVID WHOLLEY SENIOR VP OF RESEARCH PARTNERSHIPS 363754 0 10000 0 0 0 28500 0 17250 0 419504 0 0 0 DR STEPHANIE JAMES SENIOR VP OF SCIENCE 351650 0 0 0 0 0 28500 0 0 0 380150 0 0 0 MICHAEL SANTOS ASSOCIATE VICE PRESIDENT OF SCIENCE 289646 0 0 0 0 0 28500 0 7040 0 325186 0 0 0 MR DONALD HILL CHIEF FINANCIAL OFFICER 249979 0 5000 0 0 0 25666 0 17300 0 297945 0 0 0 MS JULIE WOLF-RODDA SENIOR VP OF DEVELOPMENT 235610 0 0 0 0 0 23285 0 16550 0 275445 0 0 0 DR JOSEPH MENETSKI ASSOCIATE VP OF RESEARCH PARTNERSHIP 232872 0 2500 0 0 0 23616 0 15765 0 274753 0 0 0 MR KEVIN A KLOCK VP OF OPERATIONS & GENERAL COUNSEL 222164 0 5000 0 0 0 23066 0 17750 0 267980 0 0 0 DR DAVID O'BROCHTA SCIENTIFIC PROGRAM MANAGER 188311 0 0 0 0 0 18824 0 16050 0 223185 0 0 0 DR KAREN TOUNTAS SCIENTIFIC PROGRAM MANAGER 186176 0 0 0 0 0 18512 0 13670 0 218358 0 0 0 DR STACEY ADAM DIRECTOR OF CANCER RESEARCH PARTNERS 191762 0 0 0 0 0 19160 0 6940 0 217862 0 0 0 BRINDA DASS SCIENTIFIC PROGRAM MANAGER 179292 0 0 0 0 0 18181 0 9690 0 207163 0 0 0 STEVEN HOFFMANN DIRECTOR OF INFLAMMATION & IMMNUNITY 171317 0 0 0 0 0 17149 0 14550 0 203016 0 0 0 MR ROBERT BALTHASER VICE PRESIDENT OF ADVANCEMENT 166026 0 0 0 0 0 16544 0 6940 0 189510 0 0 0 ABBEY MELTZER VP OF COMMUNICATIONS AND EVENTS 151421 0 2000 0 0 0 15381 0 14550 0 183352 0 0 0 X 3 845251 STOCK PRICE 0 0 0 FORM 990, PART III, LINE 4A, PROGRAM SERVICE ACCOMPLISHMENTS CONTINUED: AMP SCZ IS THE FIFTH ACCELERATING MEDICINES PARTNERSHIP INITIATIVE, AND THE FIRST TO FOCUS ON A NEUROPSYCHIATRIC DISORDER. THESE TRAILBLAZING PARTNERSHIPS TRANSFORM THE CURRENT MODEL FOR DEVELOPING NEW DIAGNOSTICS AND TREATMENTS BY BRINGING TOGETHER THE RESOURCES OF NIH AND INDUSTRY TO IMPROVE OUR UNDERSTANDING OF DISEASE PATHWAYS AND FACILITATE BETTER SELECTION OF TARGETS FOR TREATMENT. OTHER AMP INITIATIVES ARE WORKING TO SPEED THE DEVELOPMENT OF NEW DIAGNOSTICS AND TREATMENTS FOR ALZHEIMER'S DISEASE, TYPE 2 DIABETES, RHEUMATOID ARTHRITIS/LUPUS AND PARKINSON'S DISEASE. PLASMA AB ALZHEIMER'S DISEASE IS AMONG THE LEADING CAUSES OF DEATH AMONG U.S. ADULTS. BECAUSE IT GRADUALLY IMPAIRS A PERSON'S THINKING AND SOCIAL SKILLS, ALZHEIMER'S DISEASE ALSO PLACES TREMENDOUS BURDENS ON THOSE LIVING WITH THE DISORDER AS WELL THEIR FAMILIES AND CAREGIVERS. DESPITE DECADES OF RESEARCH, THERE IS NO CURE FOR ALZHEIMER'S DISEASE AND ONLY A HANDFUL OF APPROVED TREATMENTS. THE AVAILABLE TREATMENTS CAN ALLEVIATE THE SYMPTOMS OF DISEASEBUT CANNOT STOP IT FROM CONTINUING TO DAMAGE THE BRAIN. SCIENTISTS ALSO NOW BELIEVE THAT ALZHEIMER'S DISEASE MAY BEGIN DECADES BEFORE OUTWARD SIGNS, SUCH AS MEMORY LOSS, BECOME APPARENT. IN MARCH 2020, THE FNIH BIOMARKERS CONSORTIUM LAUNCHED A BOLD NEW PROJECTPLASMA A AS A PREDICTOR OF AMYLOID POSITIVITY IN ALZHEIMER'S DISEASEINTENDED TO IDENTIFY SIMPLE, EFFECTIVE TESTS TO DETECT EARLY ALZHEIMER'S DISEASE, PAVING THE WAY FOR POTENTIAL TREATMENTS THAT COULD STOP THE DISORDER BEFORE IT HAS SERIOUSLY DAMAGED THE BRAIN. THE NEW FNIH PROJECT BRINGS TOGETHER GOVERNMENT, ACADEMIC, NOT-FOR-PROFIT AND INDUSTRY EXPERTS TO COMPARE SIX DIFFERENT POTENTIAL PLATFORMS TO MEASURE BETA AMYLOID, OR ABETA, IN A PERSON'S BODY. DEPOSITS OF ABETA IN THE BRAIN CAUSE PLAQUES BETWEEN NERVE CELLS AND ARE THOUGHT TO PLAY A ROLE IN ALZHEIMER'S DISEASE. THE TESTS UNDER EVALUATION MEASURE LEVELS OF ABETA IN PLASMA, REQUIRING ONLY A SIMPLE BLOOD DRAW. THE GOAL OF THE PARTNERSHIP IS TO DETERMINE WHICH PLATFORMS FOR MEASURING ABETA IN BLOOD PLASMA CAN ACCURATELY PREDICT THE PRESENCE OF BETA AMYLOID IN THE BRAIN. AN ABETA BLOOD TEST COULD REPLACE CURRENT TOOLS FOR MEASURING BETA AMYLOID, SUCH AS PET SCANS OR TESTING OF CEREBROSPINAL FLUID, WHICH CAN BE INVASIVE, EXPENSIVE AND PAINFUL. THIS WOULD IMMEDIATELY MAKE CLINICAL TRIALS FOR ALZHEIMER'S DISEASE PREVENTION AND TREATMENT EASIER ON RESEARCHERS AND TRIAL VOLUNTEERS. OVER THE LONGER TERM, THE TEST COULD SPEED THE SEARCH FOR NEW TREATMENTS THAT TARGET THE DISEASE IN ITS EARLIEST STAGESSPARING MILLIONS OF AMERICANS FROM THE RISK OF IRREVERSIBLE BRAIN DAMAGE. FORM 990, PART VI, SECTION A, LINE 1 THE BOARD HAS AN EXECUTIVE COMMITTEE, WHICH CAN MAKE DECISIONS ON BEHALF OF THE BOARD (WITH SOME EXCEPTIONS) IN BETWEEN BOARD MEETINGS. FORM 990, PART VI, SECTION B, LINE 11B PRIOR TO THE SUBMISSION OF THE FOUNDATION FOR NIH'S FORM 990 TO THE INTERNAL REVENUE SERVICE, EACH VOTING MEMBER OF THE BOARD OF DIRECTORS SHALL BE PROVIDED WITH A COPY OF THE DRAFT FORM 990 AS APPROVED BY THE CHIEF FINANCIAL OFFICER. FORM 990, PART VI, SECTION B, LINE 12C DIRECTORS, OFFICERS AND EMPLOYEES ARE REQUIRED TO ANNUALLY SIGN A STATEMENT WHICH AFFIRMS THAT THEY HAVE: O RECEIVED A COPY OF THE CONFLICT OF INTEREST POLICY O READ, UNDERSTOOD AND AGREED TO COMPLY WITH THE POLICY O RECEIVED AND REVIEWED A LISTING OF CORPORATE AND FOUNDATION DONORS, CONTRACTORS, VENDORS, GRANTEES, PRINCIPAL INVESTIGATORS AND FINANCIAL INSTITUTIONS WITH WHOM THE FNIH HAS A CURRENT RELATIONSHIP O NO ACTUAL OR APPARENT CONFLICTS OF INTEREST OTHER THAN THOSE DISCLOSED IN THE STATEMENT. THEY MUST ALSO MAKE CERTAIN NOTIFICATIONS IN PARTICULAR CIRCUMSTANCES. THE CONFLICT OF INTEREST POLICY ALSO HAS MECHANISMS FOR HANDLING SUCH CONFLICTS. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION COMMITTEE OF THE BOARD REVIEWED AND CONCURRED WITH THE PRESIDENT AND EXECUTIVE DIRECTOR'S DECISIONS ESTABLISHING AND ADJUSTING THE SENIOR EXECUTIVE TEAM'S ANNUAL SALARIES AND RELATED COMPENSATION DECISIONS. THE COMPENSATION COMMITTEE ALSO APPROVED THE COMPENSATION LEVEL OF THE PRESIDENT AND EXECUTIVE DIRECTOR AND RELATED COMPENSATION DECISIONS. FORM 990, PART VI, SECTION C, LINE 19 ALL SUCH DOCUMENTS ARE AVAILABLE UPON REQUEST. IN ADDITION, THE GOVERNING DOCUMENTS AND FINANCIAL STATEMENTS ARE AVAILABLE ON THE FNIH WEBSITE. FORM 990, PART VII, SECTION A: DONALD M. HILL AND KEVIN A. KLOCK WERE KEY EMPLOYEES THROUGH SEPTEMBER 2020 AND WERE RECLASSIFIED AS OFFICERS STARTING OCTOBER 2020. FORM 990, PART XII, LINE 2C: PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.